文献速递造血干细胞移植与细胞治疗

CD3靶向慢病毒载体实现T细胞特异性激活与体内基因递送

Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.
PubMed 文献 · Blood Adv · 2020-01-01

本研究开发了靶向CD3的慢病毒载体(CD3-LV),无需预先激活即可选择性修饰人类T淋巴细胞,并在全血及人化NSG小鼠中实现T细胞特异性基因递送,成功在体内生成CD19特异性CAR T细胞并清除CD19+细胞。

要点

  • CD3-LV无需预先激活即可选择性转导T细胞,优于传统VSV-LV。
  • CD3-LV在全血中无额外刺激下仍具基因递送活性。
  • 人化NSG小鼠中CD3-LV体内递送CAR基因并清除CD19+细胞。

核心结论

  • CD3靶向慢病毒载体结合T细胞激活特性,适用于T细胞特异性体内基因递送。

研究设计与样本

  • 研究使用新型CD3靶向慢病毒载体(CD3-LV),以agonistic CD3特异性单链可变片段实现靶向,在人类T细胞、全血及人化NSG小鼠中评估基因递送。

主要发现

  • CD3-LV介导的激活、增殖和扩增较传统抗体介导激活更慢,因缺乏T细胞受体共刺激。
  • CD3-LV在非激活条件下选择性将基因递送至T细胞,表现优于VSV-LV基准载体。
  • CD3-LV加入全血无额外刺激时仍具基因递送活性。
  • 人化NSG小鼠中CD3-LV在所有分析器官实现CD3+ T细胞高效且独占性转导。
  • 最 promising 的CD3-LV在体内递送CD19特异性CAR至T淋巴细胞,伴随血液中人CD19+细胞清除。

临床怎么用

  • CD3-LV可用于T细胞特异性体内基因递送,避免体外激活步骤。
  • 该载体平台有望简化CAR T细胞体内生成流程。

局限性

  • CD3-LV介导的T细胞激活、增殖和扩增较传统抗体介导激活更慢。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic modification of T lymphocytes is a key issue in research and therapy. Conventional lentiviral vectors (LVs) are neither selective for T cells nor do they modify resting or minimally stimulated cells, which is crucial for applications, such as efficient in vivo modification of T lymphocytes. Here, we introduce novel CD3-targeted LVs (CD3-LVs) capable of genetically modifying human T lymphocytes without prior activation. For CD3 attachment, agonistic CD3-specific single-chain variable fragments were chosen. Activation, proliferation, and expansion mediated by CD3-LVs were less rapid compared with conventional antibody-mediated activation owing to lack of T-cell receptor costimulation. CD3-LVs delivered genes not only selectively into T cells but also under nonactivating conditions, clearly outperforming the benchmark vector vesicular stomatitis-LV glycoproteins under these conditions. Remarkably, CD3-LVs were properly active in gene delivery even when added to whole human blood in absence of any further stimuli. Upon administration of CD3-LV into NSG mice transplanted with human peripheral blood mononuclear cells, efficient and exclusive transduction of CD3+ T cells in all analyzed organs was achieved. Finally, the most promising CD3-LV successfully delivered a CD19-specific chimeric antigen receptor (CAR) into T lymphocytes in vivo in humanized NSG mice. Generation of CAR T cells was accompanied by elimination of human CD19+ cells from blood. Taken together, the data strongly support implementation of T-cell-activating properties within T-cell-targeted vector particles. These particles may be ideally suited for T-cell-specific in vivo gene delivery.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Frank AM, Braun AH, Scheib L, et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv. 2020. PMID: 33216892. doi:10.1182/bloodadvances.2020002229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。